Loading...
•
Mar 31, 2024
Amphastar Q1 2024 Earnings Report
Amphastar reported strong Q1 2024 results, driven by BAQSIMI® revenue growth and increased sales of Glucagon, Epinephrine and Phytonadione.
Key Takeaways
Amphastar Pharmaceuticals reported net revenues of $171.8 million for the three months ended March 31, 2024, a 23% increase compared to the same period in 2023. GAAP net income was $43.2 million, or $0.81 per share, while adjusted non-GAAP net income was $55.3 million, or $1.04 per share.
Net revenues reached $171.8 million in Q1 2024.
GAAP net income was $43.2 million, or $0.81 per share.
Adjusted non-GAAP net income was $55.3 million, or $1.04 per share.
BAQSIMI® revenue grew by 22% compared to the first quarter of 2023.
Revenue by Segment
Forward Guidance
The company is focused on developing, manufacturing, marketing, and selling technically-challenging generic and proprietary injectable, inhalation, and intranasal products.
Revenue & Expenses
Visualization of income flow from segment revenue to net income
Historical Earnings Impact
Analyze how earnings announcements historically affect stock price performance
Avg. Return Before/After Earnings
Loading earnings performance data...
Loading earnings reaction data...